Autoimmune and Chronic Cholestatic Disorders of the Liver

Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas

Volumn , Issue , 2009, Pages 1035-1058

  Batts, Kenneth P ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ABBOTT NORTHWESTERN HOSPITAL   (United States)

^c Minnesota Gastroenterology   (United States)

^d Hospital Pathology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882817532     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141604059-0.50042-4     Document Type: Chapter

References (115)

1. Johnson PJ, McFarlane IG Meeting report: International autoimmune hepatitis group. Hepatology 1993, 18:998-1005.
2. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
3. Yatsuji S, Hashimoto E, Kaneda H, et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: Is the International Autoimmune Hepatitis Group scoring system useful?. J Gastroenterol 2005, 40:1130-1138.
4. Czaja A Autoimmune hepatitis-approach to diagnosis. Medscape Gen Med 2006, 8:55.
5. Krawitt EL Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
6. Homberg JC, Abuaf JC, Bernard O, et al. Chronic active hepatitis associated with anti-liver/kidney/microsome antibody type I: A second type of "autoimmune" hepatitis. Hepatology 1987, 7:1333-1339.
7. Tanaka H, Tujioka H, Ueda H, et al. Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol 2005, 11:6069-6071.
8. Castell JV, Castell M Allergic hepatitis induced by drugs. Curr Opin Allergy Clin Immunol 2006, 6:258-265.
9. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: Diagnosis, grading, and staging. Hepatology 1994, 19:1513-1520.
10. Strassbourg CP, Manns MP Autoimmune hepatitis vs. viral hepatitis C. Liver 1995, 15:225-232.
11. Manns MP, Vogel A Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006, 43:S132-S144.
12. Baptista A, Bianchi L, DeGroote L, et al. The diagnostic significance of periportal hepatitic necrosis and inflammation. Histopathology 1988, 12:569-579.
13. Wang MX, Morgan T, Lungo W, et al. "Piecemeal" necrosis: Renamed troxis necrosis. Exp Mol Pathol 2001, 71:137-146.
14. Pratt DS, Fawaz KA, Rabson A, et al. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997, 113:664-668.
15. Ichiki Y, Aoki CA, Bowlus CL, et al. T cell immunity in autoimmune hepatitis. Autoimmun Rev 2005, 4:315-321.
16. Lefkowitch JH, Apfelbaum TF, Weinberg L, et al. Acute liver biopsy lesions in early autoimmune ("lupoid") chronic active hepatitis. Liver 1984, 4:379-386.
17. Burgart LJ, Batts KP, Czaja AJ Recent-onset autoimmune hepatitis: Biopsy findings and clinical correlations. Am J Surg Pathol 1995, 19:699-708.
18. Nikias GA, Batts KP, Czaja AJ The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994, 21:866-887.
19. Czaja AJ, Carpenter HA Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997, 26:459-466.
20. Czaja AJ, Carpenter HA Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001, 34:659-665.
21. Batts KP, Ludwig JL Chronic hepatitis: An update on ter-minology and reporting. Am J Surg Pathol 1995, 19:1409-1417.
22. Scheuer PJ The nomenclature of chronic hepatitis: Time for a change. J Hepatol 1995, 22:112-114.
23. Poynard T, Bedossa P, Opolon P Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1979, 349:825-832.
24. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
25. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
26. Heathcote J Treatment strategies for autoimmune hepatitis. Am J Gastroenterol 2006, 101:S630-632.
27. Gautam M, Cheruvattath R, Balan V Recurrence of autoimmune liver disease after liver transplantation: A systematic review. Liver Transpl 2006, 12:1813-1824.
28. Charatcharoenwitthaya P, Lindor KD Current concepts in the pathogenesis of primary biliary cirrhosis. Ann Hepatol 2005, 4:161-175.
29. Van de Water J, Gershwin ME, Leung P, et al. The auto-epitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med 1988, 167:1791-1799.
30. Ludwig J, Czaja AJ, Dickson ER, et al. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: Morphologic spectrum, clinical correlations, and terminology. Liver 1984, 4:105-116.
31. Rubin E, Schaffner F, Popper H Primary biliary cirrhosis: Chronic nonsuppurative destructive cholangitis. Am J Pathol 1965, 46:387-407.
32. Jones DE, Watt FE, Metcalf JV, et al. Familial primary biliary cirrhosis reassessed: A geographically-based population study. J Hepatol 1999, 30:402-407.
33. Kim WR, Lindor KD, Locke GR, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631-1636.
34. Sherlock S, Dooley J Primary biliary cirrhosis. Diseases of the Liver and Biliary System 1997, 239-9748. Blackwell Scientific, Malden, MA. 10th ed. S. Sherlock, J. Dooley (Eds.).
35. Floreani A, Betterle C, Baragiotta A, et al. Prevalence of celiac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult celiac disease patients in Italy. Dig Liver Dis 2002, 34:258-261.
36. Van de Water J, Gerson LB, Ferrell LD, et al. Immuno-histochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996, 24:1079-1084.
37. Tanaka A, Miyakawa H, Luketic VA, et al. The diagnostic value of anti-mitochondrial antibodies, especially in primary biliary cirrhosis. Cell Mol Biol (Noisy-le-Grand) 2002, 48:295-299.
38. Kouroumalis E, Notas G Pathogenesis of primary biliary cirrhosis: A unifying model. World J Gastroenterol 2006, 12:2320-2327.
39. Combes B, Markin RS, Wheeler DE, et al. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999, 30:602-605.
40. Yamazaki K, Suzuki K, Nakamura A, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999, 30:71-78.
41. Colina F, Pinedo F, Solis JA, et al. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 1992, 102:1319-1324.
42. Ludwig J, Dickson ER, McDonald GSA Staging of nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978, 379:103-112.
43. Ludwig J New concepts in biliary cirrhosis. Semin Liver Dis 1987, 7:293-301.
44. Popper H The problem of histologic evaluation of primary biliary cirrhosis. Virchows Arch A Pathol Anat Histol 1978, 379:99-102.
45. Harada K, Minato H, Hiramatsu K, et al. Epithelioid cell granulomas in chronic hepatitis C: Immunohistochemical character and histological marker of favorable response to interferon-alpha therapy. Histopathology 1998, 33:216-221.
46. Larrey D, Hadengue A, Pessayre D, et al. Carbamazepine-induced acute cholangitis. Dig Dis Sci 1987, 32:554-557.
47. Ishak KG Sarcoidosis of the liver and bile ducts. Mayo Clin Proc 1998, 73:467-472.
48. Mahl TC, Shockcor W, Boyer JL Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994, 20:707-713.
49. Gores GJ Yes, hepatocellular cancer does occur in primary biliary cirrhosis. Liver Transpl 2002, 8:570-571.
50. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 1989, 10:1-7.
51. Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989, 10:846-850.
52. Lee Y-M, Kaplan MM The natural history of PBC: Has it changed?. Semin Liver Dis 2005, 25:321-326.
53. Poupon RE, Poupon R, Balkau B Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC study group. N Engl J Med 1994, 330:1342-1347.
54. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149-1156.
55. Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759-766.
56. Lindor KD, Dickson ER, Jorgenson RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. Hepatology 1995, 22:1158-1162.
57. Batts KP, Jorgenson RA, Dickson ER, et al. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Am J Gastroenterol 1996, 91:2314-2317.
58. Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29:644-647.
59. Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002, 122:652-658.
60. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-890.
61. Goulis J, Leandro G, Burroughs AK Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 1999, 354:1053-1060.
62. Lindor KD, Poupon R, Poupon R, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000, 355:657-658.
63. Tinmouth J, Tomlinson G, Heathcote EJ, et al. Benefit of transplantation in primary biliary cirrhosis between 1985-1997. Transplantation 2002, 73:224-227.
64. Balan V, Batts KP, Porayko MK, et al. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993, 18:1392-1398.
65. Brunner G, Klinge O Ein der chronisch-destruierenden nicht-eitrigen Cholangitis ähnliches Krankheitsbild mit antinukleären Antikörpern (Immunocholangitis). Dtsch Med Wochenschr 1987, 112:1454-1458.
66. Vierling J Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis 2004, 8:177-194.
67. Taylor S, Dean P, Riely C Primary autoimmune cholangitis: An alternative to antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994, 18:91-99.
68. Michieletti P, Bassendine M, Heathcote E, et al. Antimitochondrial antibody negative primary biliary cirrhosis: A distinct syndrome of autoimmune cholangitis. Gut 1994, 35:260-265.
69. Goodman ZD, McNally PR, Davis DR, et al. Autoimmune cholangitis: A variant of primary biliary cirrhosis: Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995, 40:1232-1242.
70. Ben-Ari Z, Dhillon A, Sherlock S Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993, 18:10-15.
71. Kim WR, Poterucha JJ, Jorgenson RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997, 26:22-26.
72. Wee A, Ludwig J Pericholangitis in chronic ulcerative colitis: Primary sclerosing cholangitis of the small bile ducts. Ann Intern Med 1985, 102:581-587.
73. Angulo P, Larson DR, Therneau T, et al. Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol 1999, 94:3310-3313.
74. Abdalian R, Heathcote EJ Sclerosing cholangitis: A focus on secondary causes. Hepatology 2006, 44:1063-1074.
75. Jessurun J, Bolio-Solis A, Manivel JC Diffuse lymphoplasmacytic acalculous cholecystitis: A distinctive form of chronic cholecystitis associated with primary sclerosing cholangitis. Hum Pathol 1998, 29:512-517.
76. Buckles DC, Lindor KD, Larusso NF, et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002, 97:1138-1142.
77. Kazumori H, Ashizawa N, Moriyama N, et al. Primary sclerosing pancreatitis and cholangitis. Int J Pancreatol 1998, 24:123-127.
78. Charatcharoenwitthaya P, Lindor KD Primary sclerosing cholangitis: Diagnosis and management. Curr Gastroenterol Rep 2006, 8:75-82.
79. Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology 2003, 38:210-217.
80. Chapman RWG, Varghese Z, Gaul R, et al. Association of primary sclerosing cholangitis with HLA B-8. Gut 1983, 24:38-41.
81. Donaldson PT, Farrant JM, Wilkinson ML, et al. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991, 13:129-133.
82. MacCarty RL, LaRusso NF, Wiesner RH, et al. Primary sclerosing cholangitis: Findings on cholangiography and pancreatography. Radiology 1983, 149:39-44.
83. Nakanuma Y, Hirai N, Kono N, et al. Histological and ultrastructural examination of the intrahepatic biliary tree in primary sclerosing cholangitis. Liver 1986, 6:317-325.
84. Ludwig J, Batts KP, MacCarty RL Ischemic cholangitis in hepatic allografts. Mayo Clin Proc 1992, 67:519-526.
85. Washington K, Clavien PA, Killenberg P Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Hum Pathol 1997, 28:791-795.
86. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000, 75:688-694.
87. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002, 51:562-566.
88. Angulo P, Larson DR, Therneau TM, et al. Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol 1999, 94:3310-3313.
89. Kaya M, de Groen PC, Angulo P, et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: The Mayo Clinic experience. Am J Gastroenterol 2001, 96:1164-1169.
90. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
91. Angulo P, Maor-Kendler Y, Lindor KD Small-duct primary sclerosing cholangitis: A long-term follow-up study. Hepatology 2002, 35:1494-1500.
92. Boberg KM, Rocca G, Egeland T, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002, 35:652-657.
93. Ludwig J, Barham SS, LaRusso NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981, 1:632-640.
94. Batts KP Ischemic cholangitis. Mayo Clin Proc 1998, 73:380-385.
95. Gomez M, Scotto B, Roger R, et al. Ischemic cholangitis after ligation of the hepatic artery: A case report. J Radiol 2002, 83:736-738.
96. Graziadei IW, Joseph JJ, Wiesner RH, et al. Increased risk of chronic liver failure in adults with heterozygous alpha-1-antitrypsin deficiency. Hepatology 1998, 28:1058-1063.
97. Ludwig J Idiopathic adulthood ductopenia: An update. Mayo Clin Proc 1998, 73:285-291.
98. Cullen SN, Chapman RW The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006, 26:52-61.
99. van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998, 29:417-423.
100. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001, 53:308-312.
101. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Develop-ment of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: Outcome after endoscopic treatment. J Hepatol 2002, 36:151-156.
102. Graziadei IW Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002, 8:575-581.
103. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999, 29:1050-1056.
104. Beuers U, Rush C Overlap syndromes. Semin Liver Dis 2005, 25:311-320.
105. Schramm C, Lohse AW Overlap syndromes of cholestatic liver diseases and autoimmune hepatitis. Clin Rev Allergy Immunol 2005, 28:105-114.
106. Kingham JGC, Abbasi A Co-existence of primary biliary cirrhosis and primary sclerosing cholangitis: A rare overlap syndrome put in perspective. Eur J Gastroenterol Hepatol 2005, 17:1077-1080.
107. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 2001, 33:544-554.
108. Jeyamani R, Ramakrishna BS, Kurian G Eosinophilic cho-langiopathy-a report of two cases. Indian J Gastroenterol 2007, 26:190-191.
109. Northover JM, Terblanche J A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 1979, 66:379-384.
110. Nakano S, Haratake J, Hashimoto H Alterations in bile ducts and peribiliary microcirculation in rats after common bile duct ligation. Hepatology 1995, 21:1380-1386.
111. Urushihara N, Ariki N, Oyama T, et al. Secondary sclerosing cholangitis and portal hypertension after O157 enterocolitis: Extremely rare complications of hemolytic uremic syndrome. J Pediatr Surg 2001, 36:1838-1840.
112. Gelbmann CM, Rümmele P, Wimmer M, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 2007, 102:1221-1229.
113. Xia X, Demorrow S, Francis H, et al. Cholangiocyte injury and ductopenic syndromes. Semin Liver Dis 2007, 27:401-412.
114. Vuppalanchi R, Chalasani N, Saxena R Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol 2006, 30:1619-1623.
115. Hubscher SG, Lumley MA, Elias E Vanishing bile duct syndrome: A possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 1993, 17:70-77.